APOLLO Study

- Safety and Performance of INVICTA DF4 Ventricular Defibrillation Lead:

Results From the APOLLO Prospective Multicenter Study –

K. K. Witte, J. G. Martínez, M. M. Oliveira, et al. " Safety and Performance of INVICTA DF4 Ventricular Defibrillation Lead: Results From APOLLO Prospective Multicenter Study." Pacing and Clinical Electrophysiology (2026): . https://doi.org/10.1111/pace.70286

Background & objectives

Implantable cardioverter-defibrillators (ICDs) are a cornerstone therapy for patients at high risk of life-threatening ventricular arrhythmias.

The RV defibrillation lead is a critical component of ICD therapy.

Objective:
→ Evaluate the safety and performance of the **INVICTA DF4 ventricular defibrillation lead** in patients undergoing de novo ICD/CRT-D implantation.

Primary endpoints (evaluated at 3 months)
→ Freedom from RV lead-related complications
→ RV pacing threshold (0.5 ms)

Secondary endpoints (evaluated at 24 months)
→ Electrical performance
→ Defibrillation efficacy
→ Lead-related complications
→ Implant handling and success
→ Adverse events

Methodology

Study design:
→ Prospective
→ Multicenter
→ Single-arm European study
→ 24-month follow-up

8 European countries

45 Hospitals

446 Patients enrolled

Results

100% implant success

Electrical performance (24 months):
→ Pacing threshold: **0.85 V** ± 0.33 V
→ Sensing: **13.4 mV** ± 3.17 mV
→ Pacing impedance: **525 Ω** ± 94.2 Ohms

97.7% Successful shock therapy

96.4% Complication-free survival



Conclusion

→ Excellent implant success and stable electrical performance through 24 months
→ Low lead-related complication rates with effective ventricular arrhythmia termination
→ Comparable electrical performance between RV septal and apical lead placement

REFER TO THE PRODUCT MANUAL FOR COMPLETE INSTRUCTIONS FOR USE AVAILABLE AT MICROPORTMANUALS.COM
NOT AVAILABLE FOR DISTRIBUTION OR SALE IN THE USA. MICROPORTCARDIOFLOW - JULY 2026 –RE06400133- A - EN